Endocrine

Gynecomastia: workup and management

Clinical Overview and When to Suspect Gynecomastia

— Requires ≥2 cm of palpable, concentric, rubbery subareolar tissue to be clinically significant

— Distinct from pseudogynecomastia (lipomastia), which is fatty enlargement without true glandular proliferation

— Neonatal (maternal estrogen transfer; resolves in weeks)

— Pubertal (ages 10–14, peaks at Tanner stages 3–4; resolves in 1–2 years in ~90%)

— Older men (ages 50–80; declining testosterone, rising SHBG, increased peripheral aromatization in adipose tissue)

— Onset outside the three physiologic windows

— Rapid progression, asymmetry, pain, or size >5 cm (macromastia)

— Associated systemic symptoms: weight loss, testicular mass, visual field defects, hyperthyroid features, liver stigmata

— New medication exposure temporally linked to onset

— ↑ Estrogen production (testicular/adrenal tumor, hCG-secreting tumor, aromatase excess)

— ↑ Peripheral aromatization (obesity, cirrhosis, hyperthyroidism)

— ↓ Androgen production or action (primary/secondary hypogonadism, Klinefelter, antiandrogens)

— Drug-induced (spironolactone, ketoconazole, finasteride, cimetidine, anabolic steroids withdrawal)

Board pearl: True gynecomastia is firm, concentric, mobile subareolar tissue; eccentric, hard, fixed, or bloody-discharge masses mandate evaluation for male breast cancer (especially in Klinefelter syndrome, 20–50× risk).

Definition: Benign proliferation of glandular breast tissue in males due to an imbalance between estrogen (stimulatory) and androgen (inhibitory) action at the breast.

Epidemiology — three physiologic peaks:

When to suspect pathologic gynecomastia:

Pathophysiology framework — always think estrogen:androgen ratio:

Ambulatory triage mindset: Most cases in primary care are physiologic, idiopathic, or drug-induced — reserve aggressive endocrine/imaging workup for red-flag features.

Presentation Patterns and Key History

— Painful or tender unilateral subareolar lump (early proliferative phase, <6 months)

— Painless bilateral enlargement (chronic, fibrotic phase, >12 months — less likely to regress)

— Cosmetic concern without symptoms (especially adolescents and older men)

— Incidental finding on chest exam or imaging

— Florid/proliferative phase (<6 months): glandular hyperplasia, edema — responsive to medical therapy

— Intermediate phase (6–12 months): transitional

— Fibrotic phase (>12 months): dense stromal fibrosis — only surgery effective

— Onset, duration, laterality, pain, nipple discharge

— Pubertal milestones, fertility history, libido, erectile function, shaving frequency

— Testicular pain, mass, or trauma; cryptorchidism history

— Systemic: weight changes, heat intolerance, palpitations, jaundice, edema

— Family history of breast cancer (male or female), BRCA, Klinefelter

— Definite association: spironolactone, cimetidine, ketoconazole, flutamide/bicalutamide, finasteride, GnRH agonists, anabolic steroids, estrogens

— Probable: calcium channel blockers, ACE inhibitors, amiodarone, isoniazid, methadone, HAART (efavirenz), risperidone, metoclopramide

— Substances: alcohol (cirrhosis + direct testicular toxicity), marijuana, opioids, lavender/tea tree oil (topical phytoestrogens), heroin

Step 3 management: In an outpatient with new gynecomastia, your first move is a complete medication reconciliation including OTCs and supplements before ordering any labs — drug-induced gynecomastia accounts for 10–25% of adult cases and resolves with discontinuation if caught in the proliferative phase.

Chief complaint variations:

Timeline matters for management:

Targeted history checklist:

Medication and exposure review — must be exhaustive:

Occupational/environmental: embalming fluid, pesticides, occupational estrogen exposure (pharmaceutical workers)

Physical Exam Findings and Systemic Assessment

— Patient supine, hands clasped behind head

— Pinch technique: thumb and forefinger gently brought together from lateral chest toward nipple

— True gynecomastia: firm, rubbery, mobile, concentric disc of tissue beneath the areola, often tender

— Pseudogynecomastia: soft, no discrete disc, tissue feels uniform with surrounding fat

— Suspicious for malignancy: hard, fixed, eccentric (not centered under nipple), skin dimpling, nipple retraction, bloody discharge, axillary lymphadenopathy

— Diameter of glandular tissue (cm), laterality, tenderness, skin changes

— Photograph if available for longitudinal comparison

— Testicular size (normal 4×3 cm, volume 15–25 mL by Prader orchidometer)

— Small/firm testes → Klinefelter (XXY); small/soft → secondary hypogonadism

— Testicular mass → Leydig, Sertoli, or germ cell tumor (hCG-secreting)

— Asymmetric testicular size with unilateral gynecomastia is a red flag

— Liver: spider angiomata, palmar erythema, caput medusae, ascites, gynecomastia of cirrhosis

— Thyroid: goiter, tremor, lid lag, tachycardia (hyperthyroidism increases SHBG and aromatization)

— Pituitary: bitemporal hemianopsia, galactorrhea (prolactinoma → secondary hypogonadism)

— Adrenal: Cushingoid features, virilization, hypertension (adrenal tumor)

— Renal: uremic stigmata; CKD alters hormone clearance

— Cardiovascular: stable vitals — gynecomastia itself is not hemodynamic

Key distinction: A hard, eccentric, fixed unilateral mass with skin changes or bloody nipple discharge is breast cancer until proven otherwise — proceed directly to diagnostic mammography and ultrasound, not endocrine workup. Male breast cancer accounts for ~1% of all breast cancers but is more often advanced at presentation.

Breast exam technique:

Measure and document:

Genitourinary exam — mandatory:

Systemic clues by organ system:

Diagnostic Workup — Initial Labs and Imaging

— Skip labs in clear-cut pubertal or drug-induced cases with reassuring exam — reassess in 6 months

— hCG (human chorionic gonadotropin) — testicular germ cell tumor, hepatoma, lung cancer

— Total and free testosterone (morning, 8–10 AM, fasting)

— LH and FSH — distinguishes primary (↑LH/FSH, ↓T) vs secondary (↓ or normal LH/FSH, ↓T) hypogonadism

— Estradiol — elevated in Leydig/Sertoli tumors, adrenal tumors, aromatase excess

— TSH and free T4 — hyperthyroidism increases SHBG and aromatization

— Prolactin — does NOT directly cause gynecomastia but causes hypogonadotropic hypogonadism (and galactorrhea)

— LFTs and creatinine — cirrhosis and CKD alter clearance and SHBG

— ↑ hCG → testicular ultrasound + CT chest/abdomen/pelvis (extragonadal germ cell, hepatoma, bronchogenic)

— ↑ Estradiol, normal hCG → testicular ultrasound first; if negative, adrenal CT/MRI

— ↓ Testosterone + ↑ LH/FSH → primary hypogonadism → karyotype if small firm testes (Klinefelter)

— ↓ Testosterone + ↓/normal LH/FSH → pituitary MRI, prolactin, iron studies (hemochromatosis)

— ↑ TSH-suppressed, ↑ free T4 → treat hyperthyroidism

— All normal → idiopathic gynecomastia (~25% of adult cases)

— Suspicious exam features (hard, fixed, eccentric, bloody discharge, lymphadenopathy)

— Diagnostic mammography (sensitivity ~90% for male breast cancer) + targeted ultrasound

— Biopsy any BI-RADS 4 or 5 lesion

Board pearl: Always order hCG first in adult gynecomastia with red flags — a missed hCG-secreting germ cell tumor is a classic Step 3 vignette and the only diagnosis that mandates immediate oncologic evaluation.

When to order labs: Pathologic features (rapid growth, size >5 cm, asymmetry, signs of systemic disease, prepubertal onset, or failure to regress in adolescents after 2 years).

First-tier laboratory panel:

Interpretive framework:

Breast imaging — when:

Diagnostic Workup — Advanced and Confirmatory Studies

— Detects nonpalpable Leydig cell tumors (often <2 cm) and seminomas

— Bilateral microlithiasis in setting of gynecomastia warrants follow-up

— Indicated when testes are small (<6 mL), firm, with elevated LH/FSH and low testosterone

— Klinefelter: tall stature, eunuchoid proportions, infertility (azoospermia), learning difficulties, 20–50× increased risk of male breast cancer, increased risk of mediastinal germ cell tumors

— Indicated when LH/FSH inappropriately low for low testosterone, or if prolactin elevated

— Look for prolactinoma, nonfunctioning macroadenoma, craniopharyngioma

— Indicated when estradiol elevated, hCG normal, testicular ultrasound negative

— Feminizing adrenocortical carcinoma is rare but classic — usually >6 cm at diagnosis

— 24-hour urine free cortisol or overnight dexamethasone suppression if Cushingoid features

— Iron studies (ferritin, transferrin saturation) if hypogonadotropic hypogonadism — hemochromatosis deposits in pituitary and testes

— Genetic testing for androgen insensitivity (partial AIS) in young adults with gynecomastia + infertility + ambiguous secondary sexual development

— Aromatase excess syndrome (CYP19A1 mutation) — rare familial; consider in prepubertal gynecomastia with advanced bone age

— Reserved for indeterminate mammographic findings (BI-RADS 4/5)

— Excisional biopsy not first-line — leads to unnecessary cosmetic deformity

CCS pearl: On a CCS case, after ordering testicular ultrasound, advance the clock 1–2 days to obtain results before committing to surgery or oncologic referral; ordering operative resection before imaging confirmation will cost you points.

Testicular ultrasound: Indicated for any palpable testicular abnormality, elevated hCG or estradiol, or unexplained primary hypogonadism.

Karyotype (47,XXY) for Klinefelter syndrome:

Pituitary MRI with contrast:

Adrenal CT or MRI:

Additional targeted studies:

Core needle biopsy:

Risk Stratification and First-Line Management Logic

— Discontinue offending medication (substitute eplerenone for spironolactone, switch finasteride to alternative for BPH if feasible)

— Treat hyperthyroidism, cirrhosis decompensation, hypogonadism (testosterone replacement)

— Resect Leydig/Sertoli/germ cell or adrenal tumor

— Treat prolactinoma with cabergoline

— Proliferative (<6 months, tender, soft glandular tissue) → responsive to medical therapy or spontaneous resolution

— Fibrotic (>12 months, painless, dense) → medical therapy ineffective; surgery only

— Reassurance and observation: physiologic pubertal gynecomastia, idiopathic with no red flags, mild and non-bothersome → reassess in 3–6 months

— Medical therapy: proliferative phase + significant pain/distress + identifiable hormonal driver, OR prophylaxis in prostate cancer patients on antiandrogens

— Surgical referral: fibrotic, cosmetically distressing, >12-month duration, failed medical therapy, suspicion of malignancy

— Tanner stage 3–4 gynecomastia, <4 cm, <2 years duration → reassure, monitor every 6 months

— Persistence beyond 2 years or size >4 cm → endocrine evaluation and consider treatment

— Prepubertal gynecomastia is never normal — full workup required

— Carefully weigh medication burden; many "idiopathic" cases are polypharmacy-driven

— Screen for hypogonadism but do not reflexively prescribe testosterone — exogenous T can paradoxically worsen gynecomastia via aromatization

Step 3 management: The most common ambulatory misstep is jumping to tamoxifen or surgery before reviewing the medication list, checking testicular exam, and ordering basic labs; always pause for these three steps first.

Step 1: Identify and treat the underlying cause. Curing the etiology is the single most effective intervention.

Step 2: Assess phase of gynecomastia (critical for therapy choice):

Step 3: Stratify by management pathway:

Adolescent-specific algorithm:

Older adult algorithm:

Pharmacotherapy — First-Line Drug Regimens

— Proliferative-phase gynecomastia (<6 months) with significant tenderness or psychological distress

— Prophylaxis or treatment of gynecomastia in men on antiandrogen therapy for prostate cancer (bicalutamide)

— Adjunct in pubertal gynecomastia persisting >2 years before fibrosis sets in

— Dose: 10–20 mg PO daily for 3–6 months

— Response rate: ~80% partial reduction, ~60% complete resolution in proliferative phase

— Off-label use in the US for benign gynecomastia (FDA-approved for breast cancer)

— Side effects: hot flashes, mild GI upset, rare VTE risk, retinal changes at high doses

— Monitor: clinical breast exam at 1, 3, and 6 months

— 60 mg PO daily; particularly studied in adolescents

— May be slightly more effective than tamoxifen in pubertal gynecomastia per small trials

— Not recommended for routine adult gynecomastia — RCTs show no clear benefit over placebo

— Limited role in aromatase excess syndrome and select pediatric cases

— Only for confirmed hypogonadism with low testosterone — restores estrogen:androgen balance

— Risk: peripheral aromatization can paradoxically worsen gynecomastia; consider transdermal over injectable

— Contraindicated in untreated prostate cancer, erythrocytosis (Hct >54%), untreated severe OSA

— Single fraction (8–15 Gy) to breast bud prior to or shortly after starting bicalutamide for prostate cancer — reduces incidence of gynecomastia by ~50%

Board pearl: Tamoxifen 10–20 mg daily × 3–6 months is the highest-yield first-line pharmacologic answer for symptomatic, proliferative-phase gynecomastia — aromatase inhibitors are a distractor.

Indications for pharmacologic therapy:

Tamoxifen (selective estrogen receptor modulator) — first-line:

Raloxifene (alternative SERM):

Aromatase inhibitors (anastrozole, letrozole):

Testosterone replacement:

Prophylactic radiotherapy:

Surgical Management and Procedural Considerations

— Fibrotic-phase gynecomastia (>12 months) unresponsive to medical therapy

— Macromastia (>5 cm or Simon grade IIb–III)

— Cosmetic and psychological distress with failure of conservative management

— Suspicion of malignancy → excisional biopsy

— Adolescent persistent gynecomastia after 2+ years (after growth plates near closure)

— Subcutaneous mastectomy (periareolar/Webster incision) — gold standard for true glandular tissue

— Liposuction — best for pseudogynecomastia or mixed presentations with predominant adipose component

— Combined approach — common in real practice; liposuction + glandular excision

— Skin-reducing mastectomy for grade III (significant skin redundancy)

— Complete hormonal workup must be finalized — do not operate on undiagnosed endocrinopathy

— Reach stable weight; significant weight loss after surgery causes recurrence/contour irregularities

— Smoking cessation 4 weeks pre-op

— Discontinue anabolic steroids and offending medications

— Compression vest for 4–6 weeks

— Drain management if placed

— Activity restriction for 2–4 weeks

— Hematoma (most common, 1–10%), seroma, infection

— Contour deformity, "saucer" deformity from over-resection

— Nipple-areolar complex necrosis (rare, more common with large grade III reductions)

— Hypertrophic scarring, nipple sensation changes

— Recurrence (5–10%, higher if underlying cause not addressed)

— Often classified as cosmetic; preauthorization may require documentation of pain, malignancy concern, or failed medical therapy

Step 3 management: Refer to plastic or general surgery only after the endocrine workup is complete and the patient has been in the fibrotic phase or failed 3–6 months of tamoxifen — premature surgical referral is a common testable error.

Indications for surgery:

Surgical techniques:

Preoperative considerations:

Postoperative care:

Complications:

Insurance and value considerations:

Special Populations — Elderly and Renal/Hepatic Impairment

— Up to 65% have palpable breast tissue on careful exam — most asymptomatic

— Driven by declining testosterone, rising SHBG (sequesters more T than E2), increased adipose aromatization, and polypharmacy

— Polypharmacy is the dominant driver: spironolactone (heart failure), digoxin, calcium channel blockers, PPIs, finasteride/dutasteride, 5α-reductase inhibitors

— Approach: meticulous medication reconciliation, deprescribe when feasible (e.g., switch spironolactone → eplerenone if HFrEF tolerates), screen for prostate disease and testicular masses, then labs only if red flags

— Avoid reflexive testosterone replacement — risks include prostate cancer progression, erythrocytosis, MACE signal in older men with cardiovascular disease per recent trials

— Mechanism: decreased testosterone production, increased LH/FSH (primary hypogonadism), uremia-induced Leydig cell dysfunction, zinc deficiency

— Dialysis patients: gynecomastia common in first months of initiating hemodialysis ("refeeding-like" mechanism resembling pubertal physiology)

— Tamoxifen: no renal dose adjustment needed

— Address: optimize dialysis, correct zinc deficiency, treat secondary hyperparathyroidism

— Mechanism: impaired hepatic clearance of androstenedione → peripheral aromatization to estrone/estradiol; increased SHBG; reduced testosterone production

— Spironolactone (used for ascites) compounds the problem — switch to eplerenone or amiloride if gynecomastia is bothersome and hypokalemia tolerable

— Tamoxifen: use cautiously in moderate-severe hepatic impairment; hepatotoxicity risk

— Lactulose, propranolol, and other portal-pressure meds are not implicated

— Weigh cosmetic surgery risks (bleeding on anticoagulation, anesthesia risk) against quality-of-life benefit

Board pearl: In a cirrhotic patient with new tender gynecomastia, the highest-yield intervention is switching spironolactone to amiloride or eplerenone — addresses both the drug effect and the underlying mineralocorticoid need.

Older adult men (>65 years):

Chronic kidney disease (CKD):

Hepatic impairment / cirrhosis:

Frailty considerations:

Special Populations — Pediatrics, Adolescents, and Athletes

— Up to 60–90% of newborns due to transplacental maternal estrogens

— Resolves spontaneously within 2–4 weeks; reassure parents

— Persistence beyond 6 months → evaluate

— Always abnormal — never reassure without workup

— Causes: exogenous estrogen exposure (mother's topical estrogens, lavender/tea tree oil shampoo, contaminated food), McCune-Albright syndrome, hCG-secreting hepatoblastoma, adrenocortical tumor, Peutz-Jeghers (Sertoli cell tumor), aromatase excess syndrome, familial

— Workup: hCG, estradiol, testosterone, LH/FSH, DHEAS, bone age, abdominal ultrasound, testicular ultrasound

— Affects up to 65% of boys at Tanner 3–4; peaks at age 13–14

— Pathophysiology: transient lag between estrogen surge (earlier) and testosterone surge (later)

— Management: reassurance, reassess every 6 months; resolves in 1–2 years in 90%

— Persistence >2 years, size >4 cm, or psychosocial distress → endocrine referral, consider tamoxifen or raloxifene, then surgery after growth completion

— Prevalence 1:600 male births; often undiagnosed until adolescence/adulthood

— Tall, eunuchoid, small firm testes, learning issues, infertility

— Lifelong breast cancer screening counseling — risk 20–50× general male population

— Testosterone replacement from puberty; monitor for gynecomastia paradoxical worsening

— Exogenous androgens aromatize → estradiol → gynecomastia

— On cessation, HPG axis suppression persists → hypogonadism + persistent gynecomastia

— Approach: nonjudgmental history, urine toxicology, semen analysis if fertility concerns, slow AAS taper with endocrine support, tamoxifen during recovery phase

Key distinction: Prepubertal gynecomastia is never physiologic — even subtle cases require full hormonal workup and tumor screening, in contrast to pubertal gynecomastia where reassurance dominates.

Neonatal gynecomastia:

Prepubertal gynecomastia (ages 1–9):

Pubertal gynecomastia (ages 10–17):

Klinefelter syndrome (47,XXY):

Athletes and anabolic-androgenic steroid (AAS) users:

Complications and Adverse Outcomes

— Body image disturbance, social withdrawal, avoidance of swimming/sports, depression, anxiety

— Particularly severe in adolescents — associated with decreased quality of life scores comparable to clinically significant chronic disease

— Higher rates of disordered eating and excessive exercise to mask appearance

— Screen with PHQ-9 in adolescents and adults with persistent gynecomastia

— Male breast cancer: lifetime risk ~1 in 1,000 general population; 20–50× higher in Klinefelter syndrome

— Often presents as eccentric, hard, fixed mass with nipple changes — misdiagnosed as gynecomastia and treated conservatively, leading to advanced-stage diagnosis

— Other missed malignancies: testicular germ cell tumor (curable if caught early), adrenocortical carcinoma, hepatocellular carcinoma, bronchogenic carcinoma (paraneoplastic hCG)

— Tamoxifen: hot flashes (common), VTE (rare, ~0.5%/yr), endometrial issues N/A in males, retinal changes at high cumulative doses, hepatotoxicity

— Testosterone replacement: erythrocytosis (Hct >54% → therapeutic phlebotomy), worsening BPH/LUTS, OSA exacerbation, prostate cancer concerns, fertility suppression, cardiovascular events in older men with CV disease per recent meta-analyses

— Surgical: hematoma, seroma, infection, contour deformity, nipple necrosis, hypertrophic scarring, recurrence

— Persistence of underlying cause (untreated hypogonadism, ongoing AAS use, continued offending drug) is the strongest predictor

— Postsurgical recurrence rates 5–10% — higher when etiology not addressed

— A common pitfall: starting tamoxifen in long-standing fibrotic gynecomastia yields disappointment — surgery is the only effective option

CCS pearl: If a vignette describes a man with hard, fixed, eccentric breast mass with bloody nipple discharge, do not order a hormonal panel first — order diagnostic mammography and ultrasound, then core needle biopsy if BI-RADS 4/5. Misclassifying breast cancer as gynecomastia is the highest-stakes error tested.

Psychosocial complications (most clinically impactful):

Missed malignancy:

Iatrogenic complications:

Recurrence after treatment:

Failure to regress in fibrotic phase:

When to Escalate Care — Referral and Inpatient Triage

— Suspicion of testicular torsion with associated acute scrotal pain (rare overlap, but testicular pathology often coexists)

— Suspected hCG-secreting choriocarcinoma with respiratory symptoms (pulmonary metastases, hemoptysis)

— Adrenal crisis features in suspected adrenocortical carcinoma

— Severe hyperthyroidism / thyroid storm with gynecomastia as one of many manifestations

— Suspected Klinefelter syndrome requiring karyotype confirmation and lifelong management

— Confirmed primary or secondary hypogonadism needing testosterone replacement initiation and monitoring

— Pituitary mass on MRI

— Aromatase excess syndrome, partial androgen insensitivity, or other rare genetic etiologies

— Pediatric/prepubertal gynecomastia

— Palpable testicular mass or testicular ultrasound abnormality

— Elevated hCG without identifiable source — testicular ultrasound first

— Concurrent infertility evaluation

— Confirmed germ cell tumor, adrenocortical carcinoma, or male breast cancer

— Fibrotic-phase gynecomastia, failed medical therapy, macromastia, cosmetic distress

— Suspicious breast mass requiring excisional biopsy

— Adolescent with significant body image distress or depression screening positive

— Suspected AAS use disorder — addiction medicine or sports medicine referral

— Klinefelter, familial aromatase excess, partial AIS, or BRCA-positive families with male breast cancer history

Step 3 management: A 22-year-old bodybuilder with bilateral tender gynecomastia, small testes, and admission of AAS use does not need hospitalization — coordinate outpatient endocrinology, addiction counseling, and tamoxifen with planned semen analysis and HPG axis recovery monitoring over 6–12 months.

Gynecomastia is overwhelmingly an outpatient problem — inpatient escalation is driven by the underlying cause, not the breast finding itself.

Urgent same-day evaluation indicated for:

Endocrinology referral:

Urology referral:

Oncology referral:

Plastic surgery / general surgery referral:

Mental health / counseling:

Genetics referral:

Key Differentials — Same-Category Causes (Glandular/Breast)

— Soft, uniform, no discrete subareolar disc on pinch test

— Driven by obesity; treatment is weight loss, not pharmacotherapy or surgery for glandular tissue

— Mixed presentations common — both glandular and adipose components coexist

— Hard, fixed, eccentric (not concentric under nipple), unilateral, painless mass

— Nipple retraction, skin dimpling, bloody discharge, axillary lymphadenopathy

— Risk factors: Klinefelter syndrome, BRCA2 mutation (greater risk than BRCA1 in males), family history, chronic liver disease, radiation exposure

— Workup: diagnostic mammography + ultrasound + core needle biopsy

— Treatment: mastectomy + axillary staging; ER+ in >90% → tamoxifen adjuvant (not AIs as monotherapy in males without GnRH suppression)

— Soft, mobile, well-circumscribed, not subareolar

— Distinct from breast tissue on exam and ultrasound

— Cutaneous, mobile with skin, central punctum

— Café-au-lait macules, family history of neurofibromatosis

— Tender cord-like structure, not glandular

— Rare in males; risk factors include immunosuppression, diabetes, trauma; warmth, erythema, fluctuance

— Skin-based, slow-growing, may mimic gynecomastia if subareolar

— History of trauma, ecchymosis, evolving discoloration

Key distinction: The pinch test (thumb and forefinger drawn from lateral chest toward areola) reliably differentiates true gynecomastia (palpable concentric disc of glandular tissue) from pseudogynecomastia (no discrete disc, uniform fatty tissue) — this single bedside maneuver prevents unnecessary endocrine workup in obese patients.

Pseudogynecomastia (lipomastia):

Male breast cancer:

Lipoma of the chest wall:

Sebaceous cyst / epidermal inclusion cyst:

Neurofibroma:

Mondor disease (superficial thrombophlebitis of chest wall veins):

Mastitis / breast abscess:

Dermatofibrosarcoma protuberans or other chest wall tumors:

Hematoma post-trauma:

Key Differentials — Other-Category (Systemic) Causes

— Antiandrogens: spironolactone, flutamide, bicalutamide, finasteride, dutasteride, ketoconazole, cyproterone

— Estrogens / phytoestrogens: topical estrogens, lavender oil, tea tree oil, marijuana, large soy/flaxseed loads

— Anabolic-androgenic steroids: aromatization to estradiol

— Cardiac: digoxin (estrogen-like), amiodarone, calcium channel blockers, ACE inhibitors

— GI: cimetidine, ranitidine (less), PPIs (weak), metoclopramide

— Psychiatric: risperidone, haloperidol, tricyclic antidepressants

— Infectious disease: isoniazid, ketoconazole, efavirenz, indinavir

— Other: methadone, opioids, alcohol

— Primary (testicular failure): Klinefelter syndrome, mumps orchitis, radiation, chemotherapy, trauma, autoimmune

— Secondary (hypothalamic-pituitary): prolactinoma, hemochromatosis, Kallmann syndrome, opioid-induced, pituitary macroadenoma, traumatic brain injury

— Testicular: Leydig cell, Sertoli cell, germ cell (seminoma, embryonal, choriocarcinoma) — secrete estradiol or hCG

— Adrenal: feminizing adrenocortical carcinoma, large nonfunctioning adenoma with aromatase activity

— Extragonadal hCG-secreting: hepatocellular carcinoma, gastric carcinoma, large cell bronchogenic carcinoma, pancreatic, renal

— Pituitary: prolactinoma (via secondary hypogonadism)

— Hyperthyroidism — increased SHBG and aromatization

— Cirrhosis — impaired androgen clearance, hyperestrogenism

— CKD/dialysis — hypogonadism + altered hormone clearance

— Refeeding gynecomastia — post-malnutrition or post-burn recovery

— HIV — antiretroviral effect (efavirenz, stavudine), hypogonadism

Board pearl: The "SAKED" mnemonic for the highest-yield drugs is useful — Spironolactone, Androgens/AAS, Ketoconazole, Estrogens (and Efavirenz), Digoxin/cimetidine — these dominate testable drug-induced vignettes.

Drug-induced gynecomastia (10–25% of adult cases):

Hypogonadism:

Tumors:

Systemic illness:

Idiopathic (~25% of adult cases): Diagnosis of exclusion after thorough workup

Secondary Prevention, Discharge Planning, and Long-Term Care

— Substitute or discontinue offending drugs; document rationale in the chart for medicolegal protection

— Treat hyperthyroidism, optimize cirrhosis management, manage CKD

— Replace testosterone in confirmed hypogonadism; monitor hematocrit, PSA, lipids

— Compression vest 4–6 weeks

— No heavy lifting >10 lb for 2–4 weeks

— Drain care education if drains placed; return precautions for hematoma (sudden swelling, severe pain)

— Smoking abstinence to optimize wound healing

— Scar massage starting at 3 weeks; silicone gel sheets after 4 weeks

— Reassess at 3 and 6 months; if proliferative phase reverses, taper off and observe

— If no response by 6 months, evaluate for fibrotic transition → surgical referral

— Weight loss for pseudogynecomastia or mixed presentations — reduces peripheral aromatization

— Alcohol moderation (men: ≤2 drinks/day; abstinence preferred if cirrhosis)

— Avoid AAS, OTC "testosterone boosters," lavender/tea tree topicals

— Klinefelter syndrome: annual clinical breast exam, patient-performed self-exam, low threshold for mammography for any new finding; bone density every 2 years, lipid panel, fasting glucose annually given metabolic risk

— BRCA2 carriers (male): annual clinical breast exam from age 35, consider mammography from age 50, prostate cancer screening per shared decision-making from age 40

— AAS users in recovery: monitor LH/FSH/testosterone every 3 months until HPG axis recovers; semen analysis if fertility planning

— Communicate medication changes to all prescribers (especially cardiologist if discontinuing spironolactone for HFrEF)

— Update problem list to reflect resolved vs. persistent gynecomastia

Step 3 management: When deprescribing spironolactone in a HFrEF patient for symptomatic gynecomastia, substitute eplerenone (25–50 mg daily) to preserve mortality benefit and recheck potassium and creatinine in 1–2 weeks — never simply stop the mineralocorticoid receptor antagonist without replacement.

Resolution of underlying cause is the cornerstone:

Discharge planning after surgical gynecomastia management:

Long-term plan after tamoxifen course:

Lifestyle modifications:

Surveillance in high-risk groups:

Documentation and care transitions:

Follow-Up, Monitoring, and Counseling

— Physiologic pubertal gynecomastia, reassured: every 6 months until resolution or 2 years

— Drug discontinuation: 3 months to assess regression; 6 months to confirm

— Tamoxifen therapy: clinical breast exam at 1, 3, and 6 months; LFTs at baseline and 3 months; symptom review for hot flashes, VTE

— Post-surgery: 1–2 weeks (drain removal, wound check), 6 weeks (final compression off), 3 and 6 months (cosmetic outcome)

— Testosterone replacement: testosterone level at 3 and 6 months then annually; hematocrit at 3, 6, 12 months then annually; PSA and DRE at baseline, 3–6 months, then annually; lipid panel annually

— Tamoxifen: gynecomastia regression (caliper measurement), hot flashes (Bother score), VTE symptoms, vision changes

— Testosterone: target trough mid-normal range; avoid Hct >54%; PSA rise >1.4 ng/mL in 12 months prompts urology referral

— AAS recovery: morning testosterone, LH, FSH, semen analysis at 3, 6, 12 months

— Natural history: reassure that pubertal gynecomastia resolves in 90%; idiopathic adult gynecomastia often stable

— Body image: acknowledge psychosocial impact; screen for depression with PHQ-9; consider therapy referral

— Self-exam education: teach monthly self-breast exam in Klinefelter and BRCA2 carriers; immediate reporting of any new hard, eccentric mass

— Substance use: nonjudgmental counseling for AAS cessation; address motivations (body image, performance); harm reduction if cessation not immediately feasible

— Lifestyle: weight management, alcohol moderation, avoid topical phytoestrogens

— Discuss realistic cosmetic outcomes, scarring, recurrence risk, insurance coverage

— Provide before-and-after expectations; warn about saucer deformity if over-resected

Board pearl: Adolescent gynecomastia counseling should always pair reassurance about natural resolution with active depression and bullying screening — psychosocial morbidity is the underrecognized complication and is testable as a vignette twist.

Follow-up cadence by clinical scenario:

Monitoring parameters by therapy:

Counseling pillars:

Shared decision-making for surgery:

Ethical, Legal, and Patient Safety Considerations

— Must discuss cardiovascular risk (recent TRAVERSE trial showed non-inferiority but signals for atrial fibrillation, VTE, and acute kidney injury), erythrocytosis requiring phlebotomy, fertility suppression (often irreversible after prolonged use), prostate cancer detection bias

— Document discussion explicitly; in older men with CV disease, weigh risks individually

— Particular care in adolescents — assess maturity, parental involvement, realistic expectations

— Document psychological readiness; consider mandatory mental health evaluation in patients with body dysmorphic disorder features

— Insurance disclosure: clarify cosmetic vs. medically indicated to avoid surprise billing

— In most US states, adolescents can consent to mental health care for body image issues without parental involvement; varies by state for surgical procedures (typically parental consent required for elective surgery <18)

— AAS use disclosure: maintain confidentiality unless imminent harm; provide harm reduction

— Anabolic steroid use in competitive athletes may have governing body reporting implications; counsel on testing programs (USADA, NCAA)

— In high school athletes, balance confidentiality with safety

— Patients on tamoxifen or testosterone may be lost to follow-up at insurance transitions, residency program changes, or specialty handoffs — ensure clear documentation in problem list and active reconciliation at each visit

— Communicate medication changes (e.g., spironolactone → eplerenone) to cardiology and primary care simultaneously to prevent inadvertent reversal

— Cosmetic surgery often not covered → economic disparity in treatment access

— Document medical indications (pain, malignancy concern, depression) to support insurance approval

— Misdiagnosing male breast cancer as gynecomastia is the most common malpractice claim in this area — document the pinch test, imaging decisions, and follow-up plan in any patient with red-flag features

— Failure to recognize testicular tumor in a young man with gynecomastia is similarly high-risk

Step 3 management: When a 16-year-old requests gynecomastia surgery without parental knowledge, default to requiring parental consent for elective surgery per state law, but preserve confidentiality around the discussion itself and offer mental health support — this dual approach satisfies legal and ethical obligations.

Informed consent for testosterone replacement:

Informed consent for cosmetic surgery:

Confidentiality in adolescents:

Mandatory reporting and sports medicine:

Transition-of-care risks:

Disparities and access:

Medicolegal pitfalls:

High-Yield Associations and Rapid-Fire Clinical Facts

Key distinction: Aromatase inhibitors are not first-line for adult gynecomastia despite mechanistic appeal — RCT data favor tamoxifen (SERM) as the highest-yield, evidence-supported choice for symptomatic proliferative-phase disease. This is a frequent distractor.

Three physiologic peaks: neonatal, pubertal (10–14), older adult (50–80)

Three phases of true gynecomastia: proliferative (<6 mo, treatable medically), intermediate (6–12 mo), fibrotic (>12 mo, surgery only)

Pinch test: differentiates true (concentric disc) from pseudo (uniform fat)

Klinefelter (47,XXY): small firm testes + tall stature + infertility + 20–50× male breast cancer risk

Hard, eccentric, fixed mass + bloody discharge → mammography + biopsy, not labs

First lab to order with red flags: hCG (catches germ cell tumor, hepatoma)

Tamoxifen 10–20 mg daily × 3–6 months → first-line medical therapy in proliferative phase

AIs (anastrozole, letrozole) → not effective in routine gynecomastia

Spironolactone-induced gynecomastia in HFrEF → switch to eplerenone

Cirrhotic with spironolactone for ascites + gynecomastia → switch to amiloride or eplerenone

Bicalutamide-associated gynecomastia in prostate cancer → prophylactic breast bud radiotherapy or tamoxifen

AAS user with gynecomastia → cessation + tamoxifen + monitor HPG axis recovery

Topical lavender or tea tree oil → classic pediatric phytoestrogen exposure

Refeeding gynecomastia → mimics pubertal physiology

Hyperthyroidism mechanism: ↑ SHBG + ↑ aromatization

Hemochromatosis → pituitary deposition → hypogonadotropic hypogonadism + gynecomastia

Prolactinoma → galactorrhea + secondary hypogonadism + gynecomastia

Feminizing adrenal tumor → ↑ estradiol with normal hCG and normal testicular US

Choriocarcinoma → ↑↑↑ hCG, may have pulmonary metastases at presentation

Idiopathic accounts for ~25% of well-worked-up adult cases

Drug mnemonic SAKED: Spironolactone, AAS, Ketoconazole, Estrogens/Efavirenz, Digoxin/cimetidine

Adolescent natural history: 90% resolve within 1–2 years

Prepubertal gynecomastia: never normal — always work up

BRCA2 > BRCA1 for male breast cancer risk

Board Question Stem Patterns

— 68-year-old with HFrEF on spironolactone, digoxin, lisinopril, and metoprolol presents with bilateral tender breast enlargement. Next best step?

— Answer: Switch spironolactone to eplerenone and reassess in 3 months.

— 28-year-old man with rapid-onset unilateral breast tenderness, a palpable testicular mass. Best initial test?

— Answer: Serum β-hCG and scrotal ultrasound (germ cell tumor).

— 17-year-old tall boy with small firm testes, gynecomastia, learning difficulties, infertility risk. Diagnostic test?

— Answer: Karyotype (47,XXY).

— Cirrhotic man on spironolactone for ascites develops tender gynecomastia. Best management?

— Answer: Switch to amiloride or eplerenone.

— 13-year-old Tanner stage 3 with bilateral 3-cm tender concentric subareolar tissue, no other findings. Best next step?

— Answer: Reassurance and reassessment in 6 months.

— 62-year-old with unilateral hard, fixed, eccentric 2-cm mass with bloody nipple discharge. Next step?

— Answer: Diagnostic mammography and ultrasound (not hormonal labs).

— 24-year-old bodybuilder with tender bilateral gynecomastia, small testes, admits stanozolol use. Best management?

— Answer: Cessation of AAS, tamoxifen for symptomatic relief, monitor HPG axis recovery.

— Man starting bicalutamide for metastatic prostate cancer asks about gynecomastia prevention. Best prophylaxis?

— Answer: Prophylactic breast bud radiotherapy or tamoxifen.

— Patient with 2-year history of painless bilateral gynecomastia requests tamoxifen. Best advice?

— Answer: Tamoxifen unlikely effective in fibrotic phase; refer to surgery.

— 6-year-old boy with new breast development. Next step?

— Answer: Full hormonal workup (hCG, estradiol, DHEAS, bone age, abdominal/testicular ultrasound) — never just reassure.

CCS pearl: On a CCS case, sequence orders as history → medication reconciliation → physical exam (including testicular) → basic labs (hCG, T, LH/FSH, estradiol, TSH, LFTs) → targeted imaging based on results before any therapeutic move; jumping to tamoxifen or surgery without this sequence loses points.

Pattern 1 — The polypharmacy older man:

Pattern 2 — The hCG vignette:

Pattern 3 — The Klinefelter presentation:

Pattern 4 — The cirrhotic patient:

Pattern 5 — The reassuring adolescent:

Pattern 6 — The malignancy red flag:

Pattern 7 — The AAS user:

Pattern 8 — The prostate cancer patient on antiandrogen:

Pattern 9 — The fibrotic-phase pitfall:

Pattern 10 — The prepubertal red flag:

One-Line Recap

Gynecomastia is a clinical diagnosis driven by an imbalance in the estrogen-to-androgen ratio, where the highest-yield steps are bedside differentiation from pseudogynecomastia via the pinch test, recognition of red-flag features pointing to malignancy or pathologic hormonal sources, a careful medication review, targeted hormonal workup (hCG, testosterone, LH/FSH, estradiol, TSH, LFTs), and phase-appropriate management — reassurance for physiologic cases, tamoxifen for symptomatic proliferative-phase disease, and surgery for fibrotic-phase or cosmetically distressing presentations after the underlying cause is addressed.

— Pinch test first: concentric subareolar disc = true gynecomastia; uniform fatty tissue = pseudogynecomastia (weight loss, not pharmacotherapy)

— Red flags mandate workup: rapid growth, asymmetry, hard/fixed/eccentric mass, bloody discharge, testicular abnormality, systemic signs, prepubertal onset

— Phase determines therapy: proliferative (<6 mo) → tamoxifen 10–20 mg daily × 3–6 mo; fibrotic (>12 mo) → surgical referral

— Always reconcile medications: spironolactone, AAS, ketoconazole, finasteride, cimetidine, digoxin, and topical phytoestrogens are the most testable drug culprits

— Substitute, don't just stop: spironolactone → eplerenone in HFrEF or cirrhosis preserves clinical benefit while resolving gynecomastia

— Never reassure prepubertal gynecomastia — always pursue full hormonal and tumor workup

— Klinefelter (47,XXY) carries a 20–50× male breast cancer risk → lifelong surveillance counseling and karyotype confirmation

— Tamoxifen, not aromatase inhibitors, is the evidence-supported pharmacotherapy — AIs are a distractor

Board pearl: When in doubt on a Step 3 vignette, ask three questions in order: (1) Is this true gynecomastia by pinch test? (2) Are there red flags for malignancy or pathologic hormonal source? (3) What phase is the patient in? The answers triage every case to reassurance, workup, medical therapy, or surgery — and align with how board questions are written.

High-yield recap bullets: